Neumora Therapeutics, Inc. (NMRA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.73 (-3.20%), Market cap $0.34B, 52-week low–high $0.68 ~ $3.59.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addi
Financial statements, price targets, institutional (13F) holdings and related news for Neumora Therapeutics, Inc. are updated in real time on BlackAll Trade.
Neumora Therapeutics, Inc. trades at $0.73 (-3.20%). Real-time quotes and charts are available on BlackAll Trade.
Neumora Therapeutics, Inc. has a market cap of about $0.34B.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in t